ArticleNPJ precision oncology2022
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
Abeer J Al-Qasem et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
this paperpooled itcites it